Curatis identifies potential drug candidates for a repurposing development approach in indications with high unmet medical needs via its extensive network within the scientific and medical community, as well as within the biotech/pharmaceutical industry. Curatis invests a significant portion of its revenues and resources in its development activities.
The current pipeline is a balance of preclinical and clinical compounds with clinically validated targets.
|Molecule||Pre-clinical||Phase I||Phase II||Phase III||Registered|
|C-MOH-01||treatment of medication overuse headache*|
|C-AM-01||prevention of severe migraine with aura*|
*Curatis has spun off its two phase II development projects C-MOH-01 for the treatment of medication overuse headache and C-AM-01 for the prevention of severe migraine with aura into CapiThera Ltd (www.capithera.com).
**Amyotrophic lateral sclerosis